NASDAQ: EDITEditas Medicine Inc Stock
$3.23+0.15 (+4.87%)
Updated Sep 4, 2026
EDIT Price
$3.23
Fair Value Price
N/A
Market Cap
$496.06M
52 Week Low
$1.66
52 Week High
$4.54
P/E
-4.68x
P/B
4.71x
P/S
8.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$47.01M
Earnings
-$73.95M
Gross Margin
100%
Operating Margin
-161.6%
Profit Margin
-157.3%
Debt to Equity
1.26
Operating Cash Flow
-$120M
Beta
2.11
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EDIT Overview
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EDIT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
EDIT
Ranked#99 of 458
Ranked#99 of 458
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.55 | A | |
| $111.62 | A | |
| $7.10 | A |
Be the first to know about important EDIT news, forecast changes, insider trades & much more!
EDIT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EDIT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EDIT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EDIT is good value based on its book value relative to its share price (4.71x), compared to the US Biotechnology industry average (5.56x)
P/B vs Industry Valuation
EDIT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EDIT due diligence checks available for Premium users.
Valuation
EDIT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.68x
Industry
10.75x
Market
40.74x
EDIT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.71x
Industry
5.56x
EDIT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EDIT's financial health
Profit margin
Revenue
$11.9M
Net Income
-$18.2M
Profit Margin
-153.3%
EDIT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
EDIT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$237.4M
Liabilities
$132.1M
Debt to equity
1.26
EDIT's short-term assets ($218.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EDIT's short-term assets ($218.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EDIT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EDIT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$29.6M
Investing
-$29.8M
Financing
$117.5M
EDIT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EDIT vs Biotech Stocks
Editas Medicine Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.